Recon: FDA staff raise concerns over Spectrum’s cancer drug ahead of adcomm; EMA calls for biosimilar interchangeability in EU
ReconJoanne S. Eglovitch
Biologics/ biosimilars/ vaccinesBiotechnologyDiagnostics/IVDsEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy